Literature DB >> 9429841

ACE inhibition, endothelial function and coronary artery lesions. Role of kinins and nitric oxide.

J V Mombouli1.   

Abstract

In healthy coronary arteries, the endothelium plays an important role in the regulation of vascular smooth muscle growth and contractility. Furthermore, the endothelium inhibits overt platelet aggregation and prevents the adhesion of white blood cells to, and their infiltration into, the vascular wall. Among the mediators of these functions of endothelial cells, nitric oxide (NO) plays a central role. Moreover, the presence of local kinin-generating enzymatic systems associated with endothelial cells, vascular smooth muscle, platelets, neutrophils and monocytes suggests that bradykinin stimulates endothelial cells to release NO locally. The activation of endothelial cells by bradykinin is inhibited by kininase II, best known as angiotensin converting enzyme (ACE). Hence, ACE inhibitors, in addition to reducing the levels of angiotensin II (a potent stimulus to vascular smooth muscle growth and contraction), cause an amplification of the release of NO and other endothelial mediators that is induced by bradykinin. Independent risk factors for coronary artery disease such as hypertension, diabetes and hypercholesterolaemia reduce the NO-dependent regulation of vascular smooth muscle contractility and growth in otherwise normal coronary arteries. This endothelial dysfunction probably also affects the inhibitory role of NO with regard to platelet aggregation and monocyte infiltration into the vascular wall. In atherosclerotic vessels, the role of NO is severely reduced. In animal models, as well as in patients with coronary artery disease, endothelial dysfunction is improved by treatment with ACE inhibitors. Although in humans the mechanism of the restoration of endothelial function is not known, in animals endogenous kinins and NO are involved. However, it is clear that this process is multifactorial, and thus probably involves both the prevention of the deleterious actions of angiotensin II and the potentiation of bradykinin.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9429841     DOI: 10.2165/00003495-199700545-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  81 in total

Review 1.  The preclinical basis of the therapeutic evaluation of losartan.

Authors:  P B Timmermans; P C Wong; A T Chiu; R D Smith
Journal:  J Hypertens Suppl       Date:  1995-07

Review 2.  Endothelial protection by converting enzyme inhibitors.

Authors:  G Wiemer; B A Schölkens; W Linz
Journal:  Cardiovasc Res       Date:  1994-02       Impact factor: 10.787

3.  Changes in components of kinin system and hemodynamics in acute myocardial infarction.

Authors:  K Hashimoto; H Hamamoto; Y Honda; M Hirose; S Furukawa; E Kimura
Journal:  Am Heart J       Date:  1978-05       Impact factor: 4.749

4.  Endothelium-dependent relaxation to the B1 kinin receptor agonist des-Arg9-bradykinin in human coronary arteries.

Authors:  G R Drummond; T M Cocks
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

5.  Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation.

Authors:  R D Farhy; O A Carretero; K L Ho; A G Scicli
Journal:  Circ Res       Date:  1993-06       Impact factor: 17.367

6.  Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death.

Authors:  A J Marian; Q T Yu; R Workman; G Greve; R Roberts
Journal:  Lancet       Date:  1993-10-30       Impact factor: 79.321

7.  Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors.

Authors:  W B Campbell; D Gebremedhin; P F Pratt; D R Harder
Journal:  Circ Res       Date:  1996-03       Impact factor: 17.367

8.  Previous exposure to bradykinin unmasks an endothelium-dependent relaxation to the converting enzyme inhibitor trandolaprilat in isolated canine coronary arteries.

Authors:  B Desta; M Nakashima; M Kirchengast; P M Vanhoutte; C M Boulanger
Journal:  J Pharmacol Exp Ther       Date:  1995-02       Impact factor: 4.030

9.  Inhibition of RNA synthesis by bradykinin involves both the B1 and B2 receptor subtypes.

Authors:  L Yau; M Pinsk; P Zahradka
Journal:  Arch Biochem Biophys       Date:  1996-04-01       Impact factor: 4.013

10.  Loss of endothelial pertussis toxin-sensitive G protein function in atherosclerotic porcine coronary arteries.

Authors:  H Shimokawa; N A Flavahan; P M Vanhoutte
Journal:  Circulation       Date:  1991-02       Impact factor: 29.690

View more
  10 in total

1.  Silent Partner in Blood Vessel Homeostasis? Pervasive Role of Nitric Oxide in Vascular Disease.

Authors:  Ruba S Deeb; Brian D Lamon; David P Hajjar
Journal:  Curr Hypertens Rev       Date:  2009-11-01

2.  Stimulation of bradykinin B2-receptors on endothelial cells induces relaxation and contraction in porcine basilar artery in vitro.

Authors:  A Miyamoto; S Ishiguro; A Nishio
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

3.  Protective effects of heparin on endothelial cells in sepsis.

Authors:  Jianqi Ma; Jinghui Bai
Journal:  Int J Clin Exp Med       Date:  2015-04-15

Review 4.  Bradykinin-mediated cardiovascular protective actions of ACE inhibitors. A new dimension in anti-ischaemic therapy?

Authors:  W J Remme
Journal:  Drugs       Date:  1997       Impact factor: 9.546

Review 5.  Endothelial dysfunction, inflammation, and apoptosis in diabetes mellitus.

Authors:  Inge A M van den Oever; Hennie G Raterman; Mike T Nurmohamed; Suat Simsek
Journal:  Mediators Inflamm       Date:  2010-06-15       Impact factor: 4.711

6.  No effects on myocardial ischaemia in patients with stable ischaemic heart disease after treatment with ramipril for 6 months.

Authors:  Ronnie Willenheimer; Steen Juul-Möller; Lennart Forslund; Leif Erhardt
Journal:  Curr Control Trials Cardiovasc Med       Date:  2001

7.  Comparison of endothelial function improvement estimated with reactive hyperemia index between ramipril and telmisartan in hypertensive patients.

Authors:  You-Jeong Ki; Jae-Bin Seo; Hack-Lyoung Kim; Woo-Hyun Lim; Hye Yeon Seo; Jin Yong Lee; Woo-Young Chung
Journal:  Clin Hypertens       Date:  2017-02-15

Review 8.  Endothelial effects of antihypertensive treatment: focus on irbesartan.

Authors:  Roberto Negro
Journal:  Vasc Health Risk Manag       Date:  2008

Review 9.  Endothelial dysfunction in diabetes mellitus.

Authors:  Hadi A R Hadi; Jassim Al Suwaidi
Journal:  Vasc Health Risk Manag       Date:  2007

10.  Disrupted Nitric Oxide Metabolism from Type II Diabetes and Acute Exposure to Particulate Air Pollution.

Authors:  Ashley P Pettit; Howard Kipen; Robert Laumbach; Pamela Ohman-Strickland; Kathleen Kelly-McNeill; Clarimel Cepeda; Zhi-Hua Fan; Louis Amorosa; Sara Lubitz; Stephen Schneider; Andrew Gow
Journal:  PLoS One       Date:  2015-12-14       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.